Infliximab (infliximab, analog), Etanercept (etanercept, etanercept) and Adalimumab (adalimumab), all three agents are biologic agents that antagonize TNF-α and have been used abroad for the treatment of ankylosing spondylitis that is active or has failed to respond to treatment with NSAIDS or other drugs. A 2007 meta-analysis study showed that the three available anti-TNF agents mentioned above had similar efficacy in the treatment of ankylosing spondylitis, with significant improvement in outcome and control of disease stability. However, the long-term efficacy of antitumor necrosis factor therapy remains uncertain, with one observational study showing that the initial response appears to last at least two years. The use of antitumor necrosis factor antagonists may also reduce the frequency of recurrences of uveitis. Patients who do not respond to or are intolerant of one of the anti-TNF agents may respond to another agent. Ixepro, a recombinant human soluble tumor necrosis factor receptor fusion protein, binds reversibly to TNF-α and competitively inhibits the binding of TNFα to the TNF receptor site. It is administered as 25-50 mg of this product by subcutaneous injection once or twice a week. Patients may continue the original dose of anti-rheumatic drugs during treatment. It may improve the condition, such as morning stiffness, back pain, tendon terminal inflammation, chest expansion degree, blood sedimentation and C-reactive protein. The main adverse effect of this product is infection.